Onconova Therapeutics Announces Participation at Upcoming Virtual Events
September 09 2020 - 8:00AM
Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical
company focused on discovering and developing novel products to
treat cancer, today announced that the Company plans to participate
in several upcoming events:
- Marcus Evans Healthcare Investment Webinar
- Participation on panel titled “Exploring ESG Investment
Opportunities in Healthcare amidst COVID-19” on Thursday, September
10 at 1:00 PM ET
- H.C. Wainwright 22nd Annual Global Investment
Conference
- Company presentation on Monday, September 14 at 1:30 PM ET
- Webcast information:
https://wsw.com/webcast/hcw7/ontx/1639361
- 2nd Annual RAS-Targeted Drug Development Conference
- Company presentation titled “Rigosertib as a Unique Small
Molecule RAS Antagonist: Scientific & Clinical Studies” on
Wednesday, September 16 at 11:30 AM ET and panel discussion at
12:50 PM ET
About Onconova Therapeutics,
Inc.Onconova Therapeutics is a biopharmaceutical company
focused on discovering and developing novel products to treat
cancer. Using a proprietary chemistry platform, the Company has
created a pipeline of targeted anti-cancer agents designed to
disrupt specific cellular pathways that are important for cancer
cell proliferation. Onconova’s RAS pathway inhibitor, oral
rigosertib, is currently in a Phase 1/2 investigator-initiated
study (IIS) targeting patients with KRAS+ lung adenocarcinoma in
combination with nivolumab. Preclinical work with rigosertib in
COVID-19 is underway as well. Onconova is in preclinical
development with its novel, proprietary, CDK4/6 + ARK5 inhibitor,
ON 123300.
For more information, please visit
https://www.onconova.com.
Forward-Looking StatementsSome
of the statements in this release are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995,
and involve risks and uncertainties. These statements relate to
Onconova expectations regarding its clinical development plans and
patents. Onconova has attempted to identify forward-looking
statements by terminology including "believes," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes. Although Onconova
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors, including the success and timing
of Onconova's clinical trials and regulatory approval of protocols,
Onconova’s ability to continue as a going concern, the need for
additional financing, our collaborations including the effective
termination of the HanX license and securities purchase agreements
and plans for partnering certain territories, and those discussed
under the heading "Risk Factors" in Onconova's most recent Annual
Report on Form 10-K and quarterly reports on Form 10-Q. Any
forward-looking statements contained in this release speak only as
of its date. Onconova undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
Press release contact
information
Company Contact:
Avi OlerOnconova Therapeutics, Inc.267-759-3680
ir@onconova.ushttps://www.onconova.com/contact/
MediaDavid Schull, Russo Partners LLC: (212)
845-4271Nic Johnson, Russo Partners LLC: (212) 845-4242
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Sep 2023 to Sep 2024